C
CG ONCOLOGY, INC. COMMON STOCK
NASDAQ: CGON (CG Oncology, Inc.)
最近更新时间: 8小时之前75.10
0.25 (0.33%)
| 前收盘价格 | 74.85 |
| 收盘价格 | 74.97 |
| 成交量 | 598,423 |
| 平均成交量 (3个月) | 1,053,675 |
| 市值 | 6,656,891,904 |
| 价格/销量 (P/S) | 1.11 |
| 股市价格/股市净资产 (P/B) | 5.75 |
| 52周波幅 |
| 营业利益率 (TTM) | -81,161.54% |
| 稀释每股收益 (EPS TTM) | -1.50 |
| 季度收入增长率 (YOY) | -90.20% |
| 总债务/股东权益 (D/E MRQ) | 0.15% |
| 流动比率 (MRQ) | 30.97 |
| 营业现金流 (OCF TTM) | -81.98 M |
| 杠杆自由现金流 (LFCF TTM) | -57.18 M |
| 资产报酬率 (ROA TTM) | -12.85% |
| 股东权益报酬率 (ROE TTM) | -16.58% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | CG Oncology, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
1.2
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 1.17 |
|
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 1.17% |
| 机构持股比例 | 105.34% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合